Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.81 |
| ▸ | PARP1 | P09874 | 6/20 | 0.81 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | F3 | P13726 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 2/20 | 0.44 |
| ▸ | TYMS | P04818 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712442 | 1.00 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL29676851 | 0.89 | PARP10 (1.00) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL123731 | 0.89 | PARP10 (1.00) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL17797572 | 0.86 | PARP10 (0.81) | PARP10PARP1PARP11PDPK1TDP2 | |
| SCHEMBL10201434 | 0.83 | PARP1 (0.56) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL19838574 | 0.79 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL15830755 | 0.79 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL31743097 | 0.79 | PARP10 (0.81) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL2062848 | 0.79 | PARP10 (0.51) | PARP10PARP1PARP11F7F3 | |
| SCHEMBL391991 | 0.78 | PARP10 (0.68) | PARP10PARP1PARP11F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4495119-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| CN-118647617-A | Fused heterocyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-117946098-A | Pyrimidine PLK1 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2023174374-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-09-21 | — | — | WO | disclosed |
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4051386-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650868-A | Small molecule degradation agent of HELIOS and use method thereof | 达纳-法伯癌症研究公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2021087093-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | IKZF2, IKZF1, HELZ | PARP10 3373/4885PARP1 3104/4885PARP11 3208/4885 |
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, MLKL | PARP10 601/4885PARP1 733/4885PARP11 386/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PARP10 2251/4885PARP1 2606/4885PARP11 2746/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PARP10 2251/4885PARP1 2606/4885PARP11 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.